Tato stránka byla automaticky přeložena a přesnost překladu není zaručena. Podívejte se prosím na anglická verze pro zdrojový text.

Cryotherapy for Bronchoscopic Management of Central Airway Obstruction: Clinical Experience at Assiut University Hospital.

16. listopadu 2026 aktualizováno: Ebtesam Adel Hammad Askar, Assiut University

The aim of this study is to evaluate the clinical efficacy of therapeutic bronchoscopic cryotherapy for management of central airway obstruction (CAO).

Přehled studie

Detailní popis

Introduction:

Central airway obstruction (CAO) is defined as significant narrowing of the trachea, main stem bronchi or the bronchus intermedius, and occurs in a wide variety of airway disorders, including endobronchial tumors, post-intubation and post-tracheostomy stenosis, post-infectious stenosis, granulation tissue, tracheomalacia, and foreign body obstruction . It is associated with a poor prognosis and impaired quality of life, even when the underlying cause is benign.

Therapeutic bronchoscopy can improve symptoms, quality of life, and survival in patients with CAO, and the current American College of Chest Physicians guideline supports a multimodality approach that includes tissue debridement, ablation, dilation, and stent placement according to the underlying disease . Recent evidence shows substantial improvements in breathlessness and quality of life after therapeutic airway interventions, with a low complication rate in a large long-term series.

Bronchoscopic cryotherapy is a pragmatic modality for recanalization of CAO that can be delivered through a flexible bronchoscope under moderate sedation, achieving more than partial airway patency in about 90% of sessions in an 11-year single-center cohort, although bleeding remains the main concern [7]. Its usefulness has also been shown in tumor-like endobronchial tuberculosis and, with the spray technique, in a prospective registry of central airway diseases . In Egypt, a single-center study reported that cryotherapy was safe and improved clinical scores, pulmonary function, and quality of life in patients with CAO of different etiologies . Evidence regarding bronchoscopic cryotherapy for CAO remains limited in our region despite its increasing clinical utilization. This study aims to assess the feasibility, safety, and clinical outcomes of bronchoscopic cryotherapy for CAO within the constraints of a resource-limited healthcare environment and evaluating our institutional experience at Assiut University Hospital.

  • The aim of this study is to evaluate the clinical efficacy of therapeutic bronchoscopic cryotherapy for management of central airway obstruction (CAO).

  • Type of the study: Prospective Interventional Study.

  • Study Group: The study will include patients diagnosed with central airway obstruction (CAO) and fit for bronchoscopy.

  • Study Setting: Respiratory bronchoscopy unit, Assuit University Hospital. Study subjects: All adult patients diagnosed with central airway obstruction(CAO) and fit for bronchoscopic intervention will be eligible.

    a. Inclusion criteria:

    • Adult patients (above 18 years old) presenting with endobronchial lesions causing central airway obstruction. and fit for bronchoscopy
    • b. Exclusion criteria:
    • Patients with coagulopathy (INR > 1.5).
    • Severe refractory hypoxemia or type 2 respiratory failure (hypoventilation with hypercapnia).
    • Severe pulmonary hypertension (PASP > 55 mmHg).
    • Hemodynamic instability.
    • Lung collapse > 2 months duration. c.Sample size calculation:

The sample size was calculated using Epi Info™️ version 7 software based on the following assumptions:

The primary outcome variable was the successful airway recanalization rate. Based on a previous study by Hussein et al. (2026), the overall successful recanalization rate (complete and partial) was 96%. Assuming an expected proportion of 96%, a confidence level of 90%, and a confidence limit (margin of error) of 5%, the minimum required sample size was estimated to be 42.

  • Study tools (in detail, e.g., lab methods, instruments, steps, chemicals, …):

Baseline Evaluation

Prior to the intervention, all candidates will undergo:

  • Clinical Assessment: Detailed history taking, physical examination, and dyspnea assessment using the modified Medical Research Council (mMRC) scale, while cough and hemoptysis were evaluated using the Walsh cough score and the Morice hemoptysis severity score, respectively.

  • Laboratory Tests: CBC, liver/kidney functions, coagulation profile, fasting blood glucose, and Arterial Blood Gases (ABG)

  • Radiological Imaging: Plain Chest X-ray (PA view) and CT chest to evaluate the site and extent of the obstruction.

  • Functional assessment : ABG and pulmonary function test pre and post procedure. Intervention Protocol (Therapeutic Bronchoscopy)

    1. General Preparation

  • Anesthesia: This procedure will be performed under local anesthesia .

  • Equipment: A flexible bronchoscope (e.g., Pentax EBK-3000) with a 3.2 mm working channel.

  • Pre-medication: Intramuscular atropine (0.5 mg) to reduce secretions and prevent vasovagal reflexes and nebulized lidocaine.

  • Mapping: Determination of the location and degree of obstruction according to the Freitag et al [8]. scheme.

    1. Specific Techniques

Bronchoscopic Cryotherapy (ERBOKRYO CA):

In a well-equipped room with monitoring of blood pressure ,heart rate ,respiratory rate and oxygen saturation.

  • Mechanism: Utilizing the Joule-Thompson effect, where high-pressure (60 bar) carbon dioxide as a cooling agent rapidly expands at the probe tip due to the difference with the atmospheric pressure, reducing the temperature to approximately - 78 °C [9].
  • Application: Procedures will be conducted under local aesthesia in one or two sessions, each lasting 30-60 min. The cryo¬probe will be inserted through the bronchoscope biopsy channel which is positioned approximately 10 mm above the lesion and the probe is in direct contact to the lesion. The lesion will be frozen for 20-60 s/cycle for three cycles to devascularize the tumor, after which the bronchoscope and cryoprobe will be removed together with adherent tissue.

IV. Follow-up Parameters

  • Immediate (Post-procedure): Chest X-ray within 2 hours to exclude pneumothorax.
  • Short-term: Monitoring for peri-procedural complications within the first 24 hours Complications were classified as minor (e.g., self-limited bleeding, transient hypoxemia, mild pneumomediastinum not requiring invasive intervention) or major (e.g., life-threatening bleeding, respiratory failure requiring ventilatory support, pneumothorax requiring chest tube insertion).This classification was conceptually aligned with the Common Terminology Criteria for Adverse Events (CTCAE) framework.
  • Bronchoscopic grading of bleeding severity; Grade 1: Bleeding requiring suctioning for less than 1 minute. Grade 2: Bleeding requiring suctioning for more than 1 minute, repeated wedging of the bronchoscope, or topical haemostatic agents.

Grade 3: Bleeding requiring selective intubation with an endotracheal tube or balloon/bronchial blocker for less than 20 minutes, or premature termination of the procedure.

Grade 4: Persistent selective intubation for more than 20 minutes, ICU admission, transfusion, bronchial artery embolisation, or resuscitation.

- Long-term: Patients will be followed for up to 3 months post-procedure, including:

  • Clinical evaluation ;

    - Quality of life (SF-36),symptoms(cough,dyspnea,hemoptysis).

  • Functional Evaluation ; ABG and spirometry.

  • Bronchoscopic evaluation (to check for re-obstruction)if clinically indicated.

  • Radiological evaluation (CT or Chest X-ray).

    • Research outcome measures:

      1. Primary (main):

Technical efficacy: Percentage of patients achieving successful airway recanalization following bronchoscopic cryotherapy, according to the Freitag et al & Hussein et al :

  1. Complete canalization: ≥90% restoration of airway lumen
  2. Partial canalization: 50-89% restoration.
  3. Failed canalization: <50% restoration or inability to proceed due to complications

b. Secondary (subsidiary):

  1. Symptomatic Improvement: Changes in dyspnea (mMRC scale),cough and hemoptysis score evaluated at short-term and at the 3-month follow-up.
  2. Safety Profile: incidence of minor and major peri-procedural complications within 24 hours, categorized using the Common Terminology Criteria for Adverse Events (CTCAE) framework.
  3. Long-term Airway Patency: Rate of re-obstruction and CAO-related re-hospitalization during the 3-month follow-up period.
  4. Overall Survival: Estimation of the 1-year overall survival (OS) rate post-intervention

Typ studie

Intervenční

Zápis (Odhadovaný)

42

Fáze

  • Nelze použít

Kontakty a umístění

Tato část poskytuje kontaktní údaje pro ty, kteří studii provádějí, a informace o tom, kde se tato studie provádí.

Studijní kontakt

  • Jméno: Ebtesam Adel Hammad Askar, Assistant Lecturer
  • Telefonní číslo: +2001012089691
  • E-mail: ebtesam6569@gmail.com

Kritéria účasti

Výzkumníci hledají lidi, kteří odpovídají určitému popisu, kterému se říká kritéria způsobilosti. Některé příklady těchto kritérií jsou celkový zdravotní stav osoby nebo předchozí léčba.

Kritéria způsobilosti

Věk způsobilý ke studiu

18 let a starší (Dospělý, Starší dospělý)

Přijímá zdravé dobrovolníky

Ne

Pohlaví způsobilá ke studiu

Všechno

Popis

Inclusion Criteria:

• Adult patients (above 18 years old) presenting with endobronchial lesions causing central airway obstruction. and fit for bronchoscopy.

Exclusion Criteria:

  • Patients with coagulopathy (INR > 1.5).
  • Severe refractory hypoxemia or type 2 respiratory failure (hypoventilation with hypercapnia).
  • Severe pulmonary hypertension (PASP > 55 mmHg).
  • Hemodynamic instability.
  • Lung collapse > 2 months duration

Studijní plán

Tato část poskytuje podrobnosti o studijním plánu, včetně toho, jak je studie navržena a co studie měří.

Jak je studie koncipována?

Detaily designu

  • Primární účel: Léčba
  • Přidělení: N/A
  • Intervenční model: Přiřazení jedné skupiny
  • Maskování: Žádné (otevřený štítek)

Zbraně a zásahy

Skupina účastníků / Arm
Intervence / Léčba
Experimentální: All adult patients diagnosed with CAO and fit for bronchoscopic intervention

Study subjects: All adult patients diagnosed with CAO and fit for bronchoscopic intervention will be eligible.

a. Inclusion criteria:

  • Adult patients (above 18 years old) presenting with endobronchial lesions causing central airway obstruction. and fit for bronchoscopy
  • b. Exclusion criteria:
  • Patients with coagulopathy (INR > 1.5).
  • Severe refractory hypoxemia or type 2 respiratory failure (hypoventilation with hypercapnia).
  • Severe pulmonary hypertension (PASP > 55 mmHg).
  • Hemodynamic instability.
  • Lung collapse > 2 months duration.

Intervention Protocol (Therapeutic Bronchoscopy)

  1. General Preparation

    • Anesthesia: This procedure will be performed under local anesthesia .
    • Equipment: A flexible bronchoscope (e.g., Pentax EBK-3000) with a 3.2 mm working channel.
    • Pre-medication: Intramuscular atropine (0.5 mg) to reduce secretions and prevent vasovagal reflexes and nebulized lidocaine.
    • Mapping: Determination of the location and degree of obstruction according to the Freitag et al [8]. scheme.

3. Specific Techniques

Bronchoscopic Cryotherapy (ERBOKRYO CA):

In a well-equipped room with monitoring of blood pressure ,heart rate ,respiratory rate and oxygen saturation.

  • Mechanism: Utilizing the Joule-Thompson effect, where high-pressure (60 bar) carbon dioxide as a cooling agent rapidly expands at the probe tip due to the difference with the atmospheric pressure, reducing the temperature to approximately - 78 °C [9].
  • Application: Procedures will be conducted under local aesthesia

Co je měření studie?

Primární výstupní opatření

Měření výsledku
Popis opatření
Časové okno
percentage of patients achieving central airway recanalization.
Časové okno: Follow up after 3 months

Successful airway recanalization following therapeutic bronchoscopic cryotherapy for central airway obstruction (CAO), defined according to the Freitag et al. and Hussein et al. criteria.

Follow up after 3 months

Sekundární výstupní opatření

Měření výsledku
Popis opatření
Časové okno
Change in Dyspnea Severity.
Časové okno: baseline and at 3 months follow up

Change from baseline in dyspnea evaluated using the modified Medical Research Council (mMRC) dyspnea scale (score range 0 to 4, where higher scores indicate worse dyspnea).

baseline and at 3 months follow up
Change in Cough Score
Časové okno: baseline and at 3 months follow up period

Change from baseline according to walsh cough score

baseline and at 3 months follow up period
Change in Hemoptysis Score
Časové okno: baseline and at 3 months follow up period

Change from baseline according to morice hemoptysis score

baseline and at 3 months follow up period
Incidence of Minor and Major Peri-procedural Complications
Časové okno: Within 24 hours post-procedure

Number of participants with treatment-related adverse events and complications, categorized by severity using the Common Terminology Criteria for Adverse Events (CTCAE) framework.

Within 24 hours post-procedure
Rate of Airway Re-obstruction and CAO-related Re-hospitalization
Časové okno: up to 3 months

Percentage of patients experiencing symptomatic airway re-obstruction or requiring re-hospitalization related to central airway obstruction (CAO).

up to 3 months
1-Year Overall Survival (OS) Rate
Časové okno: 1 year

Percentage of participants alive at 1 year following the bronchoscopic cryotherapy intervention.

1 year

Spolupracovníci a vyšetřovatelé

Zde najdete lidi a organizace zapojené do této studie.

Termíny studijních záznamů

Tato data sledují průběh záznamů studie a předkládání souhrnných výsledků na ClinicalTrials.gov. Záznamy ze studií a hlášené výsledky jsou před zveřejněním na veřejné webové stránce přezkoumány Národní lékařskou knihovnou (NLM), aby se ujistily, že splňují specifické standardy kontroly kvality.

Hlavní termíny studia

Začátek studia (Odhadovaný)

10. listopadu 2026

Primární dokončení (Odhadovaný)

10. listopadu 2027

Dokončení studie (Odhadovaný)

10. listopadu 2028

Termíny zápisu do studia

První předloženo

3. listopadu 2026

První předloženo, které splnilo kritéria kontroly kvality

16. listopadu 2026

První zveřejněno (Aktuální)

18. listopadu 2026

Aktualizace studijních záznamů

Poslední zveřejněná aktualizace (Aktuální)

18. listopadu 2026

Odeslaná poslední aktualizace, která splnila kritéria kontroly kvality

16. listopadu 2026

Naposledy ověřeno

1. listopadu 2026

Více informací

Termíny související s touto studií

Další relevantní podmínky MeSH

Další identifikační čísla studie

  • AssiutU-med-2026

Plán pro data jednotlivých účastníků (IPD)

Plánujete sdílet data jednotlivých účastníků (IPD)?

NE

Informace o lécích a zařízeních, studijní dokumenty

Studuje lékový produkt regulovaný americkým FDA

Ne

Studuje produkt zařízení regulovaný americkým úřadem FDA

Ne

Tyto informace byly beze změn načteny přímo z webu clinicaltrials.gov. Máte-li jakékoli požadavky na změnu, odstranění nebo aktualizaci podrobností studie, kontaktujte prosím register@clinicaltrials.gov. Jakmile bude změna implementována na clinicaltrials.gov, bude automaticky aktualizována i na našem webu .

Předplatit